OKYO Pharma (NASDAQ:OKYO) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of OKYO Pharma (NASDAQ:OKYO) in a report released on Monday,Benzinga reports. The brokerage currently has a $7.00 target price on the stock.

OKYO Pharma Price Performance

NASDAQ:OKYO opened at $1.48 on Monday. OKYO Pharma has a twelve month low of $0.81 and a twelve month high of $1.74. The company’s 50-day moving average price is $1.31 and its 200-day moving average price is $1.17.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OKYO Pharma stock. FNY Investment Advisers LLC bought a new position in shares of OKYO Pharma Limited (NASDAQ:OKYO) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 20,000 shares of the company’s stock, valued at approximately $25,000. FNY Investment Advisers LLC owned about 0.06% of OKYO Pharma as of its most recent SEC filing. Institutional investors and hedge funds own 2.97% of the company’s stock.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.